Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder : Results of a Double-Blind, Placebo-Co... von RICKELS, Karl, MATHEW, Sanjay, BANOV, Michael D, ZIMBROFF, Daniel L, OSHANA, Scott, PARSONS, Edward C, DONAHUE, Stephen R, KAUFFMAN, Michael, IYER, Ganesh R, REINHARD, John F

Volltext

Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam von Rickels, Karl, Pollack, Mark H, Feltner, Douglas E, Lydiard, R. Bruce, Zimbroff, Daniel L, Bielski, Robert J, Tobias, Kathy, Brock, Jerri D, Zornberg, Gwen L, Pande, Atul C

Volltext

Patient and rater education of expectations in clinical trials (PREECT) von Zimbroff, D L

Volltext

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia von ZIMBROFF, D. L, KANE, J. M, TAMMINGA, C. A, DANIEL, D. G, MACK, R. J, WOZNIAK, P. J, SEBREE, T. B, WALLIN, B. A, KASHKIN, K. B

Volltext

Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial von Daniel, David G, Zimbroff, Dan L, Potkin, Steven G, Reeves, Karen R, Harrigan, Edmund P, Lakshminarayanan, Mani

Volltext

Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder: Results of a 12-Week Core Study and 40-Week Extension von SZEGEDI, Armin, CALABRESE, Joseph R, STET, Let, MACKLE, Mary, JUN ZHAO, PANAGIDES, John

Volltext

The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy von Daniel, David G, Zimbroff, Dan L, Swift, Rachel H, Harrigan, Edmund P

Volltext

Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial von Potkin, Steven G, Alphs, Larry, Hsu, Chuanchieh, Ranga Rama Krishnan, K, Anand, Ravi, Young, Frederick K, Meltzer, Herbert, Green, Alan

Volltext

Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT) von Meltzer, Herbert Y, Alphs, Larry, Green, Alan I, Altamura, A. Carlo, Anand, Ravi, Bertoldi, Alberto, Bourgeois, Marc, Chouinard, Guy, Islam, M. Zahur, Kane, John, Krishnan, Ranga, Lindenmayer, J.-P, Potkin, Steven

Volltext

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group von Zimbroff, D L, Kane, J M, Tamminga, C A, Daniel, D G, Mack, R J, Wozniak, P J, Sebree, T B, Wallin, B A, Kashkin, K B

Volltext

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group von Daniel, D G, Zimbroff, D L, Potkin, S G, Reeves, K R, Harrigan, E P, Lakshminarayanan, M

Volltext